Very late-onset hepatitis B reactivation following chemoimmunotherapy

References

• Hu TT, Song XF, Lei Y, et al. Expansion of circulating TFH cells and their associated molecules: involvement in the immune landscape in patients with chronic HBV infection. Virol J. 2014;11:54.
   PubMed Web of Science ®Google Scholar
• Sasadeusz J, Grigg A, Hughes P, et al. Screening and prophylaxis to prevent hepatitis B reactivation: patients with hematological and solid tumor malignancies. Clin Liver Dis. 2019;23(3):511–519.
   PubMed Web of Science ®Google Scholar
• Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22(5):1170–1180.
   PubMed Web of Science ®Google Scholar
• Wang B, Mufti G, Agarwal K. Reactivation of hepatitis B virus infection in patients with hematologic disorders. Haematologica. 2019;104(3):435–443.
   PubMed Web of Science ®Google Scholar
• Perrillo RP, Gish R, Falck-Ytter YT. American gastroenterological association institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221–244.e3.
   PubMed Web of Science ®Google Scholar
• Cho Y, Yu SJ, Cho EJ, et al. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis b patient with non-Hodgkin’s lymphoma. J Med Virol. 2016;88(6):1010–1017.
   PubMed Web of Science ®Google Scholar
• Huang H, Li X, Zhu J, et al. Entecavir vs. lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312(23):2521–2530.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599.
   PubMed Web of Science ®Google Scholar
• Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020;38:31.
   Web of Science ®Google Scholar
• Doyle J, Raggatt M, Slavin M, et al. Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement. Med J Aust. 2019;210:10.
   Web of Science ®Google Scholar
• Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol. 2010;23(1):145–153.
   PubMed Web of Science ®Google Scholar
• Gill S, Carney D, Ritchie D, et al. The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. Ann Oncol 2010; 21(2):331–334.
   Google Scholar
• Nakaya A, Fujita S, Satake A, et al. Delayed HBV reactivation in rituximab-containing chemotherapy: how long should we continue anti-virus prophylaxis or monitoring HBV-DNA? Leuk Res. 2016;50:46–49.
   PubMed Web of Science ®Google Scholar
• Garcia-Rodriguez MJ, Canales MA, Hernandez-Maraver D, et al. Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment? Am J Hematol. 2008;83(8):673–675.
   PubMed Web of Science ®Google Scholar
• Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31(22):2765–2772.
   PubMed Web of Science ®Google Scholar
• Zachou K, Sarantopoulos A, Gatselis NK, et al. Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: a hidden threat. World J Hepatol. 2013;5(7):387–392.
   PubMedGoogle Scholar
• Perceau G, Diris N, Estines O, et al. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol. 2006;155(5):1053–1056.
   PubMed Web of Science ®Google Scholar
• Zoppoli G, Bruzzone B, Caligiuri P, et al. From a medical mistake to a clinical warning: the case of HBV mutant virus reactivation in haematological patients. Br J Haematol. 2008;144:961–972.
   PubMed Web of Science ®Google Scholar
• Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin Infect Dis. 2015;61(5):719–729.
   PubMed Web of Science ®Google Scholar
• Hui SK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of preemptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut. 2005;54(11):1597–1603.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Hsu C, Song YQ, et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia lymphoma study group. Eur J Cancer. 2013;49(16):3486–3496.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Ikeda M, Kumada T, et al. Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents. Hepatol Res. 2015;45(12):1220–1227.
   PubMed Web of Science ®Google Scholar
• Liu WP, Wang XP, Zheng W, et al. Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma. Leuk Lymphoma. 2016;57(6):1355–1362.
   PubMed Web of Science ®Google Scholar
• Matsubara T, Nishida T, Shimoda A, et al. The combination of anti‑HBc and anti‑HBs levels is a useful predictor of the development of chemotherapy‑induced reactivation in lymphoma patients with resolved HBV infection. Oncol Lett. 2017;14:6543–6552.
   PubMed Web of Science ®Google Scholar
• Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014;32(33):3736–3743.
   PubMed Web of Science ®Google Scholar
• Ceccarelli L, Salpini R, Sarmati L, et al. Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy. J Infect. 2012;65(2):180–183.
   PubMed Web of Science ®Google Scholar
• Chew E, Thursky K, Seymour JF. Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance. Leuk Lymphoma. 2014;55(4):938–939.
   PubMed Web of Science ®Google Scholar
• Kim EB, Kim DS, Park SJ, et al. Hepatitis B virus reactivation in a surface antigen-negative and antibody-positive patient after rituximab plus CHOP chemotherapy. Cancer Res Treat. 2008;40(1):36–38.
   PubMedGoogle Scholar
• Tonziello G, Pisaturo M, Sica A, et al. Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma. Infection. 2013;41(1):225–229.
   PubMed Web of Science ®Google Scholar
• Muraishi J, Shibata M, Honma Y, et al. Reactivation of occult hepatitis B virus infection 27 months after the end of chemotherapy including rituximab for malignant lymphoma. Intern Med. 2017;56(15):1967–1971.
   PubMed Web of Science ®Google Scholar
• Yamada T, Nannya Y, Suetsugu A, et al. Late reactivation of hepatitis B virus after chemotherapies for hematological malignancies: a case report and review of the literature. Intern Med. 2017;56(1):115–118.
   PubMed Web of Science ®Google Scholar
• Ciccullo A, Ponziani FR, Maiolo E, et al. Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma: a case report. Infection. 2019;47(2):313–316.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Abe K, Fujita M, et al. Hepatitis B virus reactivation in a patient with nonalcoholic steatohepatitis 41 months after rituximab-containing chemotherapy. Intern Med. 2019;58(3):375–380.
   PubMed Web of Science ®Google Scholar
• Dominguez N, Manzano ML, Munoz R, et al. Late reactivation of occult hepatitis B virus infection in a patient with chronic lymphocytic leukemia after rituximab and fludarabine-based regimen. Leuk Lymphoma. 2015; 56(4):1160–1163.
   PubMed Web of Science ®Google Scholar